Fractyl Health, Inc. is an innovative metabolic therapeutics company based in Lexington, Massachusetts, focused on addressing the pressing global health challenges of type 2 diabetes (T2D) and obesity. Leveraging cutting-edge research and development, Fractyl aims to transform the treatment landscape with novel therapies that target the underlying mechanisms of these conditions. The company is committed to improving patient outcomes by advancing scientific solutions that not only manage symptoms but also tackle the root causes of metabolic diseases.